FDA and Foreign Trial Monitoring: What the OIG Report Said-And What It Didn't
This article was originally published in RPM Report
Executive Summary
June's report from the Inspector General of the Department of Health and Human Services on foreign clinical trials is a stark reminder that the pharma industry's reputation problems are alive and unwell. Here is the storyline at its most basic: A global industry that conducts research in many countries to serve patients in many more does its product testing in many countries as well.
You may also be interested in...
Specialty Drug Tier: When Special Means Expensive
Medicare led the way to create a policy that’s just plain mean. Is there any way back?
Pharma's Stake In Essential Health Benefits
The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
What's Next for Broadcast DTC Advertising?
Defending DTC is one thing. But getting defensive about it is a big mistake.